Piramal Pharma to Invest $90M to Expand US Manufacturing Facilities

• Piramal Pharma Limited is investing $90 million to expand its facilities in Lexington, KY and Riverview, MI, responding to growing US customer demand and the push for onshoring drug supply.

• The expansions will enhance the company’s CDMO capabilities, particularly in sterile injectables and high potency APIs used in bioconjugates.

Piramal Pharma Limited has announced a $90 million investment to expand two of its manufacturing sites in the United States, aligning with growing demand for domestic drug production and the trend toward onshoring pharmaceutical supply chains. The investment was revealed in conjunction with the 2025 SelectUSA Investment Summit.

The company is expanding its facilities in Lexington, Kentucky, and Riverview, Michigan. Both are brownfield expansions funded through a mix of internal accruals and bank loans. The Lexington site, which focuses on sterile injectable drug products, will gain 24,000 square feet of manufacturing space and a new laboratory. New equipment will include a filling line, two commercial-scale lyophilizers, a specialised capping machine, and an external vial washer. This site is expected to be fully operational by late 2027.

In Riverview, Piramal Pharma is adding a new commercial-scale suite for the development and manufacturing of payload-linkers—high potency APIs used in antibody-drug conjugates (ADCs) and other bioconjugate drugs. This addition supports the company’s integrated ADC programme, branded ADCelerate™, and is set to go online before the end of 2025.

According to the press release, the site upgrades are expected to improve support for integrated ADC projects and bolster Piramal Pharma’s biologics contract manufacturing services. These developments aim to provide customers with shorter timelines and broader capabilities for commercial-scale drug production.

“Since its inception, Piramal Pharma Ltd has invested $570 million in its US drug development and manufacturing capabilities,” said Peter DeYoung, Chief Executive Officer, Global Pharma. “The US is our largest market, where we currently employ approximately 750 people.”

The company’s expansions in Kentucky and Michigan complement previous investments in Sellersville and Bethlehem, Pennsylvania, further strengthening its US footprint as a CDMO partner.